Primary source: Consultez le rapport de l’enquête nationale de pharmacovigilance sur les toxicités graves des spécialités contenant du 5
Translated From French
PV Bulletin does not take any responsibility for translation errors or omissions, though it has used the best available translation engine.
Mandatory DPD deficiency screening is now required for all patients prior to initiating treatment with fluoropyrimidines.
This regulatory change is crucial to prevent severe adverse effects in patients due to DPD deficiency, ensuring safer administration of chemotherapy.
Healthcare providers must implement mandatory DPD screening for all patients before starting fluoropyrimidine treatment and enhance monitoring for adverse effects.
Regulatory Intelligence Lead
Ongoing monitoring of compliance and adverse effects.
Healthcare providers must implement mandatory DPD screening for all patients before starting fluoropyrimidine treatment and enhance monitoring for adverse effects.
The ANSM has recommended enhanced monitoring and adjustment of doses for chemotherapies based on fluoropyrimidines, specifically capecitabine and 5-FU, to mitigate risks of severe adverse effects associated with these treatments, as highlighted by ongoing pharmacovigilance inquiries.
What changed: Mandatory DPD deficiency screening is now required for all patients prior to initiating treatment with fluoropyrimidines.
Why it matters: This regulatory change is crucial to prevent severe adverse effects in patients due to DPD deficiency, ensuring safer administration of chemotherapy.
Practical implication: Healthcare providers must implement mandatory DPD screening for all patients before starting fluoropyrimidine treatment and enhance monitoring for adverse effects.
Published from the regulator source ingestion pipeline after PV impact triage.
Importers of the affected glass containers must guarantee the payment of the anti-dumping duty for a period of six months from the effective date.
Organizations must review and update compliance protocols in response to expanded trade prohibitions and prepare for restrictions on Iranian aviation effective immediately.
Review and adjust labeling and compliance processes for affected combination products as per the new regulations.
Stakeholders should prepare for discussions regarding veterinary medicinal product reviews, specifically focusing on maximum residue limits and ensure all interests are declared by participants.
